{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:29:46Z","timestamp":1771644586674,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03171-0","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:03:38Z","timestamp":1719929018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity"],"prefix":"10.1007","volume":"44","author":[{"given":"\u015eenol","family":"Sabanc\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Fatih","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u00e7in","family":"S\u00fcren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet Kazim","family":"Erol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"9","key":"3171_CR1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123(9):1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"issue":"2","key":"3171_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, Holmstr\u00f6m G (2013) Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol 91(2):170\u2013175. https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02351.x","journal-title":"Acta Ophthalmol"},{"key":"3171_CR3","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/iae.0b013e3181cb6151","volume":"30","author":"KA Drenser","year":"2010","unstructured":"Drenser KA, Trese MT, Capone A Jr (2010) Aggressive posterior retinopathy of prematurity. Retina 30:S37-40. https:\/\/doi.org\/10.1097\/iae.0b013e3181cb6151","journal-title":"Retina"},{"issue":"5","key":"3171_CR4","first-page":"339","volume":"100","author":"H Funatsu","year":"1996","unstructured":"Funatsu H, Hori S, Yamashita H, Kitano S (1996) Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy. Nippon Ganka Gakkai Zasshi 100(5):339\u2013349","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"7","key":"3171_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.oftal.2011.05.008","volume":"86","author":"I Gonz\u00e1lez Viejo","year":"2011","unstructured":"Gonz\u00e1lez Viejo I, Ferrer Novella C, Pueyo Royo V (2011) Uso de anti-VEGF (anti-vascular endothelial growth factor) en la retinopat\u00eda del prematuro [use of anti-VEGF (anti-vascular endothelial growth factor) in retinopathy of prematurity (ROP)]. Arch Soc Esp Oftalmol 86(7):207\u2013208. https:\/\/doi.org\/10.1016\/j.oftal.2011.05.008","journal-title":"Arch Soc Esp Oftalmol"},{"key":"3171_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajo.2006.05.048","volume":"142","author":"N Azuma","year":"2006","unstructured":"Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S (2006) Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol 142:636\u2013643. https:\/\/doi.org\/10.1016\/j.ajo.2006.05.048","journal-title":"Am J Ophthalmol"},{"key":"3171_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2015","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z (2015) Intravitreal bevacizumab monotherapy for type-prethreshold, threshold, and aggressive posterior retinopathy of prematurity\u201427 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 253:1677\u20131683. https:\/\/doi.org\/10.1007\/s00417-014-2867-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3171_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5935\/0004-2749.20170009","volume":"80","author":"EA Sukgen","year":"2017","unstructured":"Sukgen EA, Ko\u00e7luk Y (2017) The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 80(1):30\u201334. https:\/\/doi.org\/10.5935\/0004-2749.20170009","journal-title":"Arq Bras Oftalmol"},{"issue":"5","key":"3171_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.18240\/ijo.2022.05.10","volume":"15","author":"Q Zou","year":"2022","unstructured":"Zou Q, Zhu YQ, Zhang FJ, Liu QP (2022) Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity. Int J Ophthalmol 15(5):753\u2013759. https:\/\/doi.org\/10.18240\/ijo.2022.05.10","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"3171_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5935\/0004-2749.20180005","volume":"81","author":"S Dikci","year":"2018","unstructured":"Dikci S, Ceylan OM, Demirel S, Y\u0131lmaz T (2018) Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: Lower or higher dose? Arq Bras Oftalmol 81(1):12\u201317. https:\/\/doi.org\/10.5935\/0004-2749.20180005","journal-title":"Arq Bras Oftalmol"},{"issue":"23","key":"3171_CR11","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.4103\/0366-6999.194638","volume":"129","author":"XJ Li","year":"2016","unstructured":"Li XJ, Yang XP, Sun S, Lyu XB, Jia H (2016) Intravitreal ranibizumab for aggressive posterior retinopathy of prematurity. Chin Med J (Engl) 129(23):2879\u20132881. https:\/\/doi.org\/10.4103\/0366-6999.194638","journal-title":"Chin Med J (Engl)"},{"key":"3171_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102582","author":"SD Nicoar\u0103","year":"2015","unstructured":"Nicoar\u0103 SD, Nascutzy C, Cristian C, Irimescu I, \u0218tef\u0103nu\u021b AC, Zaharie G, Drugan T (2015) Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone I stage 3+ and aggressive posterior retinopathy of prematurity. J Ophthalmol. https:\/\/doi.org\/10.1155\/2015\/102582","journal-title":"J Ophthalmol"},{"issue":"6","key":"3171_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/jop.2011.0060","volume":"27","author":"BC Harder","year":"2011","unstructured":"Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC (2011) Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther 27(6):623\u2013627. https:\/\/doi.org\/10.1089\/jop.2011.0060","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"3171_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/aos.12461","volume":"92","author":"SW Park","year":"2014","unstructured":"Park SW, Jung HH, Heo H (2014) Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Acta Ophthalmol 92(8):810\u2013813. https:\/\/doi.org\/10.1111\/aos.12461","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"3171_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/iae.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, J\u00e4ger M, Mais C, Stieger S, Andrassi-Darida M (2017) Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37(1):97\u2013111. https:\/\/doi.org\/10.1097\/iae.0000000000001126","journal-title":"Retina"},{"issue":"3","key":"3171_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/iae.0b013e31822c290f","volume":"32","author":"MW Stewart","year":"2012","unstructured":"Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF (2012) Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor trap-eye). Retina 32(3):434\u2013457. https:\/\/doi.org\/10.1097\/iae.0b013e31822c290f","journal-title":"Retina"},{"issue":"7","key":"3171_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","volume":"42","author":"EU Kabata\u015f","year":"2017","unstructured":"Kabata\u015f EU, Kurtul BE, Alt\u0131ayl\u0131k \u00d6zer P, Kabata\u015f N (2017) Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res 42(7):1054\u20131058. https:\/\/doi.org\/10.1080\/02713683.2016.1264607","journal-title":"Curr Eye Res"},{"issue":"6","key":"3171_CR18","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","volume":"42","author":"E S\u00fcren","year":"2022","unstructured":"S\u00fcren E, \u00d6zkaya D, \u00c7etinkaya E, Kalayc\u0131 M, Yi\u011fit K, K\u00fcc\u00fck MF, Erol MK (2022) Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment. Int Ophthalmol 42(6):1905\u20131913. https:\/\/doi.org\/10.1007\/s10792-021-02188-z","journal-title":"Int Ophthalmol"},{"issue":"12","key":"3171_CR19","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s10792-019-01088-7","volume":"39","author":"DY Ekinci","year":"2019","unstructured":"Ekinci DY, Vural AD, Bayramoglu SE, Onur IU, Hergunsel GO (2019) Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP. Int Ophthalmol 39(12):2697\u20132705. https:\/\/doi.org\/10.1007\/s10792-019-01088-7","journal-title":"Int Ophthalmol"},{"issue":"6","key":"3171_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.oret.2017.09.021","volume":"2","author":"M Tandon","year":"2018","unstructured":"Tandon M, Vishal MY, Kohli P, Rajan RP, Ramasamy K (2018) Supplemental laser for eyes treated with bevacizumab monotherapy in severe retinopathy of prematurity. Ophthalmol Retina 2(6):623\u2013628. https:\/\/doi.org\/10.1016\/j.oret.2017.09.021","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"3171_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3928\/01913913-20210316-01","volume":"58","author":"M Ittarat","year":"2021","unstructured":"Ittarat M (2021) Comparison of outcomes between combined sparing laser photocoagulation and intravitreal bevacizumab treatment versus conventional laser photocoagulation in aggressive posterior retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 58(5):292\u2013297. https:\/\/doi.org\/10.3928\/01913913-20210316-01","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"5","key":"3171_CR22","doi-asserted-by":"publisher","first-page":"264.e1","DOI":"10.1016\/j.jaapos.2019.05.014","volume":"23","author":"PK Shah","year":"2019","unstructured":"Shah PK, Subramanian P, Venkatapathy N, Chan RVP, Chiang MF, Campbell JP (2019) Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention. J AAPOS 23(5):264.e1-264.e4. https:\/\/doi.org\/10.1016\/j.jaapos.2019.05.014","journal-title":"J AAPOS"},{"key":"3171_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/iae.0000000000001125","volume":"37","author":"JM Yoon","year":"2017","unstructured":"Yoon JM, Shin DH, Kim SJ, Ham DI, Kang SW, Chang YS, Park WS (2017) Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina 37:88\u201396. https:\/\/doi.org\/10.1097\/iae.0000000000001125","journal-title":"Retina"},{"key":"3171_CR24","doi-asserted-by":"publisher","first-page":"778585","DOI":"10.3389\/fped.2022.778585","volume":"10","author":"AV Naravane","year":"2022","unstructured":"Naravane AV, Belin PJ, Rubino S, Quiram PA (2022) Aggressive posterior retinopathy of prematurity: long-term outcomes following intravitreal bevacizumab. Front Pediatr 10:778585. https:\/\/doi.org\/10.3389\/fped.2022.778585","journal-title":"Front Pediatr"},{"issue":"1","key":"3171_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jcjo.2018.03.005","volume":"54","author":"D Katoch","year":"2019","unstructured":"Katoch D, Dogra MR, Aggarwal K, Sanghi G, Samanta R, Handa S, Dogra M (2019) Posterior zone I retinopathy of prematurity: spectrum of disease and outcome after laser treatment. Can J Ophthalmol 54(1):87\u201393. https:\/\/doi.org\/10.1016\/j.jcjo.2018.03.005","journal-title":"Can J Ophthalmol"},{"issue":"11","key":"3171_CR26","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00417-023-06227-6","volume":"261","author":"S Obata","year":"2023","unstructured":"Obata S, Matsumoto R, Iwasa M, Kakinoki M, Sawada O, Sawada T, Saishin Y, Ohji M (2023) Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 261(11):3207\u20133213. https:\/\/doi.org\/10.1007\/s00417-023-06227-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"3171_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00417-019-04292-4","volume":"257","author":"I Perente","year":"2019","unstructured":"Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S (2019) Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol 257(6):1141\u20131146. https:\/\/doi.org\/10.1007\/s00417-019-04292-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"3171_CR28","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","volume":"88","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA (2012) Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev 88(12):937\u2013941. https:\/\/doi.org\/10.1016\/j.earlhumdev.2012.09.019","journal-title":"Early Hum Dev"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03171-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03171-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03171-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:53:28Z","timestamp":1741881208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03171-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03171-0","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Antalya Training and Research Hospital (Date:07.03.24 \/No: 2\/14).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the parents of participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"305"}}